Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jinyouli prophylaxis for neutropenia during TP chemoradiotherapy and adjuvant chemotherapy in cervical cancer
ChiCTR1900024494Phase 4Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegfilgrastim in Cervical Cancer (CC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Incidence of grade III or IV neutropenia. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
pegfilgrastim
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1900024494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024494.